Abstracts tagged "Lung Disease"

Abstract Number: 040 • 2023 Pediatric Rheumatology Symposium
HLA DRB1*15 and Eosinophilia Are Common Among Patients with Systemic Juvenile Idiopathic Arthritis
Alison Lerman¹, Shawn Mahmud¹, Zineb Alfath², Benjamin Langworthy³, Patricia Hobday¹, Mona Riskalla¹ and Bryce Binstadt¹, ¹Division of Pediatric Rheumatology, Allergy & Immunology, Department of Pediatrics, University of Minnesota and M Health Fairview Masonic Children’s Hospital, Minneapolis, MN, ²University of Minnesota, Minneapolis, ³Division of Biostatistics, School of Public Health and Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, University of Minnesota, Minneapolis, MN
Background/Purpose: Over the last two decades, some children with systemic juvenile idiopathic arthritis (SJIA) have developed a severe form of interstitial lung disease (ILD) termed…
Abstract Number: 376 • 2019 ACR/ARP Annual Meeting
Long-term Outcome and Prognostic Factors of Patients with Interstitial Pneumonia with Autoimmune Features: A Single Center Large-scale Observational Cohort Study
Okinori Murata¹, Katsuya Suzuki ², Nobuhito Sasaki ³, Tsutomu Takeuchi ² and Makoto Maemondo ³, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ³Division of Pulmonary medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Morioka, Japan
Background/Purpose: Patients with idiopathic interstitial pneumonia (IIP) may have features of connective tissue diseases (CTDs). The term interstitial pneumonia with autoimmune features (IPAF) has been…
Abstract Number: 2343 • 2019 ACR/ARP Annual Meeting
Treatment with Biologic DMARDs Does Not Increase Risk of Severe Pulmonary Events in Patients with Rheumatoid Arthritis and Pre-existing Lung Disease
Shinji Watanabe¹, Takahisa Gono ¹, Ryosuke Fukue ¹, Seiji Kobayashi ¹, Yuichiro Shirai ², Mitsuhiro Takeno ³ and Masataka Kuwana ², ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan, ³Nippon Medical School, Tokyo, Japan
Background/Purpose: Pulmonary complication is one of the leading causes of mortality in patients with rheumatoid arthritis (RA). Pre-existing lung disease is known as a risk…
Abstract Number: 1118 • 2018 ACR/ARHP Annual Meeting
Identification of Transcriptional Regulatory Networks in Systemic Sclerosis
Yue Wang¹, Jennifer Franks² and Michael L. Whitfield³, ¹Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Geisel School of Medicine at Dartmouth, Hanover, NH, ³Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous autoimmune disorder with poor outcomes and no FDA-approved therapies. Prior work has shown gene expression patterns associated with…
Abstract Number: 1123 • 2018 ACR/ARHP Annual Meeting
Plasmacytoid Dendritic Cells in Bronchoalveolar Lavage Correlate with Pulmonary Artery Diameter and Infiltrate Perivascular Areas in the Lungs from Patients with Systemic Sclerosis Associated Pulmonary Hypertension
Isela Valera¹, Anagha Divekar², Dinesh Khanna³, Fereidoun Abtin⁴, Rajan Saggar⁴ and Ram R. Singh⁴, ¹Autoimmunity and Tolerance Laboratory, Division of Rheumatology, Department of Medicine, UCLA, Los Angeles, CA, ²Biolegend, Sa Diego, CA, ³Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁴UCLA, Los Angeles, CA
Background/Purpose: In patients with systemic sclerosis (SSc), plasmacytoid dendritic cells (pDCs) increase in the bronchoalveolar lavage (BAL) and lung tissues (Kafaja S, et al, JCI…
Abstract Number: 1339 • 2018 ACR/ARHP Annual Meeting
Myositis Specific Anti-Histidyl tRNA Synthetase (HisRS) Autoantibodies Display High Reactivity Against Hisrs Conformational Epitopes and Associate with Lung and Joint Involvement
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Per-Johan Jakobsson^2,4, Susanne Graslund^1,2,3 and Ingrid E. Lundberg^1,2, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Autoimmune myositis (rheumatic muscle inflammation) associated with interstitial lung disease (ILD) and arthritis is strongly correlated with the presence of anti-histidyl tRNA synthetase (HisRS)…
Abstract Number: 1717 • 2018 ACR/ARHP Annual Meeting
Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
Dinesh Khanna^1,2, Mary Strek³, Brian Southern⁴, Rajan Saggar⁵, Vivien Hsu⁶, Maureen D. Mayes⁷, Rick Silver⁸, Virginia D. Steen⁹, Donald Zoz¹⁰ and Franck Rahaghi¹¹, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Ann Arbor, MI, ³Pulmonology, University of Chicago, Chicago, IL, ⁴Pulmonology, Cleveland Clinic Ohio, Cleavland, OH, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ⁷Rheumatology, University of Texas Medical School at Houston, Houston, TX, ⁸Rheumatology, Medical University of SC, Charleston, SC, ⁹Dept of Rheumatology, Georgetown Univ Medical Center, Washington, DC, ¹⁰Pulmonology, Boehringer Ingelheim, Ridgefield, CT, ¹¹Cleveland Clinic Florida Weston, Weston, FL
Background/Purpose: Systemic sclerosis (SSc), or scleroderma, is a rare, autoimmune, multisystem connective tissue disorder characterized by vascular damage, autoimmunity, and fibrosis of the skin and…
Abstract Number: 1740 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tocilizumab for the Treatment of Refractory Systemic Sclerosis Associated Interstitial Lung Disease: A Case Series
Judit Lluch¹, Ivan Castellvi², J Alegre³, Pablo Juárez¹, Joan Miquel Nolla¹ and Francisco Javier Narváez⁴, ¹Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²Rheumatology, Hospital Santa Creu i San Pau, Barcelona, Spain, ³Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁴Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of TCZ as as a rescue therapy in patients with refractory scleroderma-associated interstitial lung disease (SSc-ILD). Methods: We…
Abstract Number: 2462 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety in the Middle-LONG Period of Rituximab in the Treatment of Diffuse Interstitial Pulmonary Disease Associated with Rheumatoid Arthritis
Francisco Javier Narváez¹, Alejandro Robles Perez², Patricio Luburich³, J Alegre⁴, Milagros Ricse⁵, Carmen Gomez Vaquero⁶, Joan Miquel Nolla⁵ and Maria Molina⁵, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Radiology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁴Rheumatology, Hospital Universitario Doctor Peset. Valencia. Spain, Valencia, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Rheumatology Department, Hospital Universitario de Bellvitge, Idibell, Barcelona, Spain
Background/Purpose: To evaluate the efficacy and safety of rituximab (RTX) in the medium- to long-term for the management of progressive rheumatoid arthritis–related interstitial lung disease…
Abstract Number: 2919 • 2018 ACR/ARHP Annual Meeting
An Epidemic: Severe Lung Disease in Patients with Systemic Juvenile Idiopathic Arthritis, Risk Factors and Predictors
Shima Yasin¹, Christopher Towe^2,3, Ndate Fall⁴, Alexei Grom^3,4 and Grant Schulert^1,5, ¹Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pulmonology, Division of Pulmonology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ³Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, ⁴Division of Rheumatology, Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁵Pediatrics, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH
Background/Purpose: There is growing awareness of severe and often fatal chronic lung disease in patients with systemic juvenile idiopathic arthritis (sJIA). However, clinical features and…
Abstract Number: 2974 • 2018 ACR/ARHP Annual Meeting
Long-Term Survival in Lung Transplantation for Interstitial Lung Disease Due to Rheumatic Systemic Diseases. Study of 26 Cases of a Single Center
Diana Prieto Peña¹, Amaya Martinez Meñaca², Monica Calderón Goercke¹, José Luis Martín-Varillas³, Belén Atienza-Mateo³, Victor Manuel Mora Cuesta², Sonia Fernandez Rozas⁴, David Iturbe Fernandez⁴, Carmen González-Vela⁵, Jose Manuel Cifrian Martinez⁴, Miguel Angel González-Gay⁶ and Ricardo Blanco³, ¹Rheumatology, Rheumatology. Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, SANTANDER, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁴Neumology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁵Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is one of the most serious complications associated with rheumatic systemic diseases. Patients with ILD have increased mortality and limited…
Abstract Number: 2979 • 2018 ACR/ARHP Annual Meeting
Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT
Simone Barsotti^1,2, Chiara Romei³, Elisa Cioffi⁴, Claudia Roncella⁵, Elisabetta Perrone³, Alessandra Tripoli¹, Marta Mosca¹, Fabio Falaschi³ and Rossella Neri⁶, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Department of Medical Biotechnologies, University of Siena, Siena, Italy, ³Pisa University Hospital, II Radiology Unit, Pisa, Italy, ⁴Rheumatology Unit, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Pisa University Hospital, I Radiology Unit, Pisa, Italy, ⁶Rheumatology Unit, University of Pisa, PISA, Italy
Background/Purpose: Interstitial Lung Disease (ILD) in patients with Idiopathic Inflammatory Myopathies (IIM) is associated to high mortality and morbidity. The study of pleural irregularities (PI)…
Abstract Number: 2980 • 2018 ACR/ARHP Annual Meeting
Calcineurin Inhibitor for the Treatment of Myositis-Associated Interstitial Lung Disease: Comparison between Cyclosporine and Tacrolimus
Takahisa Gono¹, Kenichi Masui², Naoshi Nishina³, Shinji Sato⁴ and Masataka Kuwana¹, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ²Department of Anesthesiology, Show University Hospital, Tokyo, Japan, ³Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁴Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan
Background/Purpose: Treatment options for myositis-associated interstitial lung disease (ILD) include corticosteroids (CS) in combination with or without cyclophosphamide (CY), calcineurin inhibitors (CNIs) such as cyclosporine…
Abstract Number: 4 • 2018 ACR/ARHP Annual Meeting
Anti-Jo1 Positive Myositis Patients Display a Characteristic IgG Fc-Glycan Profile Which Is Further Enhanced in Anti-Jo1 Autoantibodies
Catia Fernandes-Cerqueira^1,2, Nuria Renard^1,2, Antonella Notarnicola^1,2, Edvard Wigren^1,2,3, Susanne Graslund^1,2,3, Roman Zubarev⁴, Ingrid E. Lundberg^1,2 and Susanna L. Lundström⁴, ¹Department of Medicine, Division of Rheumatology, Karolinska Institutet, Stockholm, Sweden, ²Center for Molecular Medicine, Stockholm, Sweden, ³Structural Genomics Consortium, Stockholm, Sweden, ⁴Department of Medical Biochemistry and Biophysics, Division of Physiological Chemistry I, Stockholm, Sweden
Background/Purpose: IgG Fc-glycans affect IgG function and are altered in autoimmune diseases and autoantibodies. Anti-histidyl tRNA synthetase autoantibodies (anti-Jo1) are frequent in myositis associated with…
Abstract Number: 70 • 2018 ACR/ARHP Annual Meeting
Colocalization of Malondialdehyde-Acetaldehyde Adducts (MAA) and Extracellular Matrix Proteins in Joint and Lung Tissues from Rheumatoid Arthritis Patients
Geoffrey M. Thiele¹, Michael J. Duryee², Jacob D. McGowan¹, Logan M. Duryee¹, Lynell W. Klassen³, James R. O'Dell³, Bryant R. England⁴ and Ted R. Mikuls⁵, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ³Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, VA Nebraska-Western Iowa Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁵Internal Medicine, Division of Rheumatology, VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Malondialdehyde-acetaldehyde adducts (MAA) are products of oxidative stress that modify self-proteins and stimulate potent cellular and humoral immune responses. We have previously demonstrated…

1
2
3
…
6
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.